Pf1801

For the treatment of CIM with PF1801 (ImmunoForge, Seoul, Korea) and/or prednisolone (Sigma, St. Louis, Montana, USA), PF1801 was dissolved in phosphate buffered salts (PBS) and PF1801 or the control vehicle (PBS) was subcutaneously administered every day from day 0 of CIM to day 14 or from day 7 of CIM, just after the measurement of grip strength, to day 21 for the prophylactic treatment or therapeutic treatment, respectively. prednisolone (PSL; Sigma‐Aldrich, St. Louis, Montana, USA) was dissolved in 0.5% (w/v) methylcellulose (Wako, Tokyo, Japan) and 5% (w/v) gamma cyclodextrin (Tokyo Chemical Industry, Tokyo, Japan). 20 mg/kg body weight (BW) of PSL or the control vehicle (0.5% methylcellulose and 5% gamma cyclodextrin) was orogastrically administered every day from day 0 of CIM to day 14 or from day 7 of CIM, just after the measurement of grip strength, to day 21 for the prophylactic treatment or therapeutic treatment, respectively. The mice were randomly allocated to each treatment or control group after the induction of CIM. Each cage housed the mice taking different treatments to minimize potential confounders.